Condition: Multiple Myeloma · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
The primary objective is to evaluate the concordance of FDG PET/CT and total body DWI MRI sequences performed during staging and at the completion of therapy. Specifically, we will assess the positivity rates, both patient-based and lesion-based (total and by district), of the two methods during staging and at the completion of therapy. An interim analysis will be conducted comparing the two methods, followed by a final prognostic analysis.
This description comes directly from the study's public registry record.
CRISTINA NANNI, MD · +390512143182 · cristina.nanni@aosp.bo.it
Always discuss trial participation with your own doctor first.
| Policlinico S.Orsola Malpighi | Bologna, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06659276